Abstract:IntroductionGlucocorticoids are a mainstay of anti-inflammatory therapy, but significant adverse effects ultimately limit their utility. Previous efforts to design glucocorticoid structures with an increased therapeutic window have focused on dissociating anti-inflammatory transcriptional repression from adverse effects primarily driven by transcriptional activation. An alternative to this medicinal chemistry approach is a systems biology based strategy that seeks to amplify selectively the anti-inflammatory activity of very low dose glucocorticoid in immune cells without modulating alternative cellular networks that mediate glucocorticoid toxicity.MethodsThe combination of prednisolone and the antithrombotic drug dipyridamole was profiled using in vitro and in vivo models of anti-inflammatory activity and glucocorticoid-induced adverse effects to demonstrate a dissociated activity profile.ResultsThe combination synergistically suppresses release of proinflammatory mediators, including tumour necrosis factor-α, IL-6, chemokine (C-C motif) ligand 5 (RANTES), matrix metalloproteinase-9, and others, from human peripheral blood mononuclear cells and mouse macrophages. In rat models of acute lipopolysaccharide-induced endotoxemia and delayed-type hypersensitivity, and in chronic models of collagen-induced and adjuvant-induced arthritis, the combination produced anti-inflammatory activity that required only a subtherapeutic dose of prednisolone. The immune-specific amplification of prednisolone anti-inflammatory activity by dipyridamole did not extend to glucocorticoid-mediated adverse effects, including corticosterone suppression or increased expression of tyrosine aminotransferase, in vivo after repeat dosing in rats. After 8 weeks of oral dosing in mice, treatment with the combination did not alter prednisolone-induced reduction in osteocalcin and mid-femur bone density, which are markers of steroid-induced osteoporosis. Additionally, amplification was not observed in the cellular network of corticotroph AtT-20/D16v-F2 cells in vitro, as measured by pro-opiomelanocortin expression and adrenocorticotropic hormone secretion.ConclusionsThese data suggest that the multi-target mechanism of low-dose prednisolone and dipyridamole creates a dissociated activity profile with an increased therapeutic window through cellular network selective amplification of glucocorticoid-mediated anti-inflammatory signaling.

Inflammation-targeted Sialic Acid-Dexamethasone Conjugates for Reducing the Side Effects of Glucocorticoids

Synthesis of an Enzyme—dependent Prodrug and Evaluation of Its Potential for Colon Targeting

Conjugation of Dexamethasone to C60 for the Design of an Anti-Inflammatory Nanomedicine with Reduced Cellular Apoptosis.

Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis.

Genetically Engineered Cell Membrane–coated Nanoparticles for Targeted Delivery of Dexamethasone to Inflamed Lungs

Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis

Development of Novel Liver-Targeting Glucocorticoid Prodrugs

Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays

Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis

Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug

Inflammation suppression by dexamethasone via inhibition of CD147-mediated NF-κB pathway in collagen-induced arthritis rats

Development and Bioactivity of Zinc Sulfate Cross-Linked Polysaccharide Delivery System of Dexamethasone Phosphate

Development and Evaluation of a Novel Biodegradable Implants with Excellent Inflammatory Response Suppression Effect by Hot-Melt Extrusion.

Supramolecular Hydrogel Dexamethasone–Diclofenac for the Treatment of Rheumatoid Arthritis

Weak acid-initiated slow release of Dexamethasone from hydrogel to treat orbital inflammation

Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers.

ZIF-8 nanoparticles coated with macrophage-derived microvesicles for sustained, targeted delivery of dexamethasone to arthritic joints

Intracellular Coassembly Boosts the Anti-Inflammation Capacity of Dexamethasone.

Delivery of Glucocorticoid Conjugate in Rat Gastrointestinal Tract and Its Treatment for Ulcerative Colitis.

Glucocorticoids-based Prodrug Design: Current Strategies and Research Progress

Dexamethasone-Loaded Thermosensitive Hydrogel Suppresses Inflammation and Pain in Collagen-Induced Arthritis Rats